PREPARATION OF A MEDICAMENT FOR ARTHRITIS AND RHEUMATISM

Abstract: The invention provides the use of therapeutically active zwitterionic aminosulfonic acids for the preparation of a medicament for the treatment of arthritis and/or rheumatism in human patients. The acids are of the kind commonly known as Good buffers. They are preferably used in making a topical medicament such as a cream, for application at a dosage of 50 µg to 5 mg of the acid per day for at least 5 days, but usually several weeks. The medicaments are non-toxic and very well tolerated, having no known side-effects.

Description: This invention relates to the use of a therapeutically active substance for the preparation of a medicament for the treatment of arthritis and/or rheumatism in human patients. Medicaments heretofore used for arthritis and rheumatism therapy have been prepared using a variety of active substances including corticosteroids such as Betamethasone, Dexamethasone, Prednisolone, Prednisone, Chloroquine, Triamcinolone and their derivatives, and non-steroid drugs including Ketoprofen, Benorylate, Aspirin®, Ibuprofen, Plenylbutazone, Indomethacin, Sulindac, Salsalate, Levamisole, Piroxicam, Fenoprofen, Naproxen, Dextropropoxyphene, Mefenamic acid, Diclofenac and their derivatives. The use of these substances is attended with many undesirable side-effects and is contraindicated in many conditions, and for many types of patients, including pregnant patients and children. Medicaments of the embrocation kind are also used but their effectiveness to date has not been convincing. These substances are believed to be active thanks to their ability to scavange free radicals. The invention seeks to provide the use of substances not heretofore proposed for medicaments for the treatment of arthritis and rheumatism, whereby the medicaments are both effective and well tolerated by the vast majority of patients. In accordance with the invention, the active substance comprises at least one of the following zwitterionic aminosulfonic acids: 2-(N-Morpholinyl)-ethane sulfonic acid (MES) 2-[N-[N′-(2-Hydroxyethyl)]-piperazinyl]-ethane sulfonic acid (HEPES], 3-[N-[N′-(2-Hydroxyethyl)]-piperazinyl]-propane sulfonic acid (HEPPS), 2-[N-[ tris -(Hydroxymethyl)]-methylamino]-ethane sulfonic acid, 2-(N-Piperazinyl)-ethane sulfonic acid, 2-(N-Piperazinyl)-propane sulfonic acid, and N,N-bis-(2-Hydroxyethyl)-2-aminoethane sulfonic acid (BES). The currently popular trivial names of some of them are given in parentheses. The acids in question are known from the chemical literature as buffers useful in biological systems. Most of them are describe among other compounds by Good, N et al , in Biochemistry 1966, 5 , 467 and have become known as Good buffers, see GB-A-2 059 768. They have been found useful in compositions for application to surfaces (including skin) to protect the surfaces against accidental adhesion during the use of cyanoacrylate-based adhesives (European Patent Application EP-A-0 080 172). They were subsequently found to give symptomatic relief in psoriasis and related skin ailments, when applied regularly to affected areas in a topical composition (European Patent Application EP-A-0 100 827). They were also known to exhibit some weak free radical scavenging activity (Hoppe-Seyler's Z. Physiol. Chem. Bd 360, S.559-570, April 1979). The most useful of these substances for the purposes of the invention is believed to be HEPES. This buffer has a pKa value of 7.31 at 37°C and is widely used in other fields, unconnected with the present invention, because of its ability to stabilise the pH of mammalian systems, eg in cell and tissue culture ("The Developing Role of the Zwitterionic Buffer" - Product information supplied by BDH (British Drug Houses) Chemicals Ltd.) HEPES takes no known part in biochemical reactions, is insoluble in organic solvents and shows no penetration of biological membranes. Thus it is not a drug as ordinarily defined. It is chemically stable and non-toxic. It has been used, inter alia , in (a) the culture of human and other mammalian cells; (b) vaccine production, eg Mycoplasma pneumoniae vaccine; (c) cryogenic tissue storage, eg animal semen; (d) production and storage of blood proteins, blood storage and lyophilized plasma specimen production; (e) the culture of bacteria, and associated enzyme assay; (f) Mycoplasma culture and identification; (g) various studies on organ and tissue samples, eg pituitary gland culture, rabbit kidney perfusion, conger eel liver culture; (h) in vitro systems in the fields of photosynthesis, oxidative phosphorylation and protein biosynthesis. It has now, surprisingly, been found that these acids have a therapeutic effect on inflammatory ailments, particularly those associated with swelling round the joints, when topically administered to a sufferer from such an ailment in a therapeutic amount over a suitable period. The inflammatory ailments in which said acids have been found to have a therapeutic effect include the conditions commonly grouped together under the terms arthritis and rheumatism. The effect does not appear to extend to such conditions when they result from trauma; it is restricted to conditions which appear to arise spontaneously, and which are presumably of systemic origin. A suitable period is a period in the range 5 days to about 6 months. A therapeutic amount, for administration over such a period, is believed to be in the range 50 µg to 50 mg per day, equivalent to half to one-quarter of that amount per application. The acid is incorporated in a pharmaceutical composition adapted for topical application, and the composition is applied to the skin on and around the affected joints once to three times a day. Suitable pharmaceutical compositions which may be prepared in accordance with the invention includes creams, ointments, gels, lotions and impregnated pads, all prepared according to recognized principles of pharmaceutical formulation. A typical cream prepared according to the invention is made up in conventional fashion from the following ingredients (percentages by weight): (a) Stearic acid 6.0 (b) Microcrystalline wax 3.0 (c) Glyceryl monostearate 2.5 (d) Polyoxyethylene sorbitan monolaurate 12.5 (e) HEPES (see above) 1.5 (f) Water qs ad 100.0 This gives an oil-in-water emulsion of the vanishing cream type (Cream A). Ingredient (d) is commercially available under the trade designation TWEEN® 20. The above cream may additionally comprise a source of copper ions such as 0.05% cupric sulfate CuSO₄.5H₂O by weight (Cream B), which appears to act synergistically in conjunction with the aminosulfonic acid. More generally, the ingredients for a typical cream may be selected from the following list, using percentage compositions, by weight of the finished creams, not exceeding the values given: Fatty acid 12.0 Vegetable oil 6.0 Glycerol monostearate 4.0 Paraffin wax 6.0 Polyoxyethylene sorbitan monoester 15.0 Zwitterionic aminosulfonic acid 4.0 Anti-fungal agent 0.1 Water qs ad 100.0 The proportion of aminosulfonic acid is within the range 0.5% to 4% by weight of the composition. Medicaments prepared in accordance with the invention can be distinguished in practice from any other medicament containing an aminosulfonic acid of the Good buffer type by the fact that they are prepared together with written information as to the relevant therapeutic purpose and/or written instructions or suggestions for their use in the treatment of arthritis or rheumatism. The invention will be illustrated now in its clinical aspect by means of the following specific non-limiting examples. Example 1 A man in his thirties had suffered from swollen and painful finger joints for over five years and, at the time of this example, was unable to flex (bend or extend) certain fingers, before treatment started. He applied Cream A (see above) once daily to the affected fingers for about three months. At the end of the treatment he had obtained full relief, full use of the fingers was restored, the swelling and pain were gone. Example 2 A male patient, aged 32, suffering from stiffness and tenderness in the arms and wrists, commenced twice daily topical application of Cream B to the wrist areas only on 25 September 1986. The symptoms disappeared completely after two weeks. Example 3 A female patient aged 50+, suffering from swelling of the knuckles and joints of the hands, with discomfort and stiffness, diagnozed by her family physician as arthritis, commenced twice daily topical application of Cream B to the affected regions on 12 July 1986. On examination three months later, it was found that the swelling of the knuckles had disappeared and normal movement of the hands had returned. There was no residual pain or discomfort. Example 4 A female patient aged 55, suffering from the condition commonly known as "frozen shoulder", with muscular contractions causing pain and incapacity, commenced twice daily topical application of Cream B to the affected regions on 1 September 1986. On examination one month later, she was found to have lost the stiffness and pain and regained normal function of the arm and shoulder. The condition of "frozen shoulder" commonly deteriorates until surgical intervention becomes necessary. After surgery, physiotherapy is required to help regain normal arm and shoulder function. Example 5 A female patient aged 76, suffering from pain and stiffness in both knee joints and unable to flex the joints normally, commenced twice daily topical application of Cream B to the affeted parts on 7 August 1986. On examination of this patient two weeks later, her knees were found to have recovered their full movement. The patient was also found able to walk upstairs normally without pain or discomfort. Example 6 A male patient aged 42, suffering from severe pain in the left hip, and receiving occasional treatment with analgesics from his family physician, commenced twice daily topical application of Cream A on 12 August 1986. Two days later the patient reported that the pain had disappeared completely. Treatment was discontinued after a total of seven days. The latest report from the patient was at the end of October 1986; he had no further pain. Thus, although more comprehensive testing is proposed, it has been demonstrated that inflammatory conditions including rheumatism and arthritis may be successfully treated by dermal absorption of the aminosulfonic acids mentioned above. The said acids are non-toxic and are not known to produce any undesirable side-effects. Thus they have considerable practice advantages over medicaments heretofore used for the treatment of inflammatory conditions, such as Phenylbutazone, Indoprofen, Indomethacin and related compounds, and may be safely administered to child patients. The pharmaceutical compositions prepared in the performance of the invention are bland, easily applied and very well tolerated. They have been tested for skin irritancy and dermatitis potential, and have been declared to meet the requirements of the United State Federal Register.

Claims: Use of a therapeutically active substance for the preparation of a topical medicament for the treatment of arthritis and/or rheumatism in human patients, characterised in that the active substance comprises at least one of the following zwitterionic aminosulfonic acids: 2-(N-Morpholinyl)-ethane sulfonic acid (MES) 2-[N-[N'-(2-Hydroxyethyl)]-piperazinyl]-ethane sulfonic acid (HEPES), 3-[N-[N'-(2-Hydroxyethyl)]-piperazinyl]- propane sulfonic acid (HEPPS), 2-[N[ tris -(Hydroxymethyl)]-methylamino]-ethane sulfonic acid, 2-(N-Piperazinyl)-ethane sulfonic acid, 2-(N-Piperazinyl)-propane sulfonic acid, and N,N-bis-(2-Hydroxyethyl)-2-aminoethane sulfonic acid (BES). Use according to claim 1, characterised in that the active substance is 2-[N-[N'-(2-Hydroxyethyl)]-piperazinyl]-ethane sulfonic acid. Use according to claim 1 or claim 2, characterised in that the medicament is a cream, an ointment, a gel, a lotion or an impregnated pad. Use according to claim 3, characterised in that the medicament is a cream, namely an oil-in-water emulsion of the vanishing cream type, and contains the active substance in a proportion from 0.5% to 4% by weight of the cream.

Inventors: O'SULLIVAN, DONNCHA
Applicants: O'SULLIVAN, DONNCHA
Application year: 1986
Main classification: A61K31
IPC codes: A61P29, A61K9, A61K31